Holen Sie sich die Stockscreener-App
12.57
0.40%
0.05
Vorhandelsmarkt:
12.60
0.03
+0.24%
Schlusskurs vom Vortag:
$12.52
Offen:
$12.57
24-Stunden-Volumen:
1.50M
Relative Volume:
0.59
Marktkapitalisierung:
$4.01B
Einnahmen:
$3.05B
Nettoeinkommen (Verlust:
$181.32M
KGV:
33.64
EPS:
0.3737
Netto-Cashflow:
$225.64M
1W Leistung:
-5.20%
1M Leistung:
+6.08%
6M Leistung:
+22.63%
1J Leistung:
+68.05%
1-Tages-Spanne:
$12.52
$13.03
1-Wochen-Bereich:
$12.35
$13.85
52-Wochen-Spanne:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.57 | 3.99B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.36 | 52.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.87 | 49.15B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.49 | 42.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.26 | 35.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
566.99 | 24.86B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | UBS | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
BlackRock (NYSE: AMRX) holds 24.1M shares, 7.6% stake reported - Stock Titan
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock - Yahoo Finance
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
AMRX Should I Buy - Intellectia AI
Amneal initiates nationwide settlement for opioid-related claims - MSN
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Returns And Recent Share Price Cooldown - Yahoo Finance
Amneal Kashiv Deal Shifts Biosimilar Growth And Valuation Story - Sahm
UBS initiates coverage of Amneal Pharmaceuticals (AMRX) with buy recommendation - MSN
Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal - MSN
Amneal Acquires Kashiv BioSciences for $750 Million Upfront - HarianBasis.co
Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push - MarketBeat
AMRX Price Today: Amneal Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
2DT Stock Price and Chart — TRADEGATE:2DT - TradingView
Why Is Amneal Pharmaceuticals Stock Gaining Today? - Sahm
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results - Yahoo Finance
Amneal agrees to buy Kashiv BioSciences - The Pharma Letter
Amneal to acquire Kashiv BioSciences in biosimilar expansion By Investing.com - Investing.com India
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal - 1470 & 100.3 WMBD
Amneal Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AMRX) 2026-04-22 - Seeking Alpha
AMRX.N Technical Analysis & Stock Price Forecast - Intellectia AI
AMRX.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AMRX News & Events - Intellectia AI
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader - Business Standard
4 Firms Build Amneal's Up To $1.1B Kashiv Biosimilars Buy - Law360
AMRX: Acquisition establishes a US biosimilars leader, targeting $1–1.3B in biosimilar revenue by 2030 - TradingView
Kashiv BioSciences to be acquired by Amneal Pharmaceuticals - ROI-NJ
Amneal Pharmaceuticals (NASDAQ:AMRX) Issues Earnings Results - MarketBeat
Amneal Pharmaceuticals to Acquire Kashiv BioSciences, Creating a Global Biosimilar Leader and Raising 2026 Financial Guidance - Minichart
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates Q1 2026 Earnings Guidance - MarketBeat
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
2.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):